Millipore Sigma Vibrant Logo

218728 Caspase-9 Inhibitor III - CAS 403848-57-7 - Calbiochem

The Caspase-9 Inhibitor III, also referenced under CAS 403848-57-7, controls the biological activity of Caspase-9. This small molecule/inhibitor is primarily used for Cancer applications.

Caspase-9 Inhibitor III - CAS 403848-57-7 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: Ac-LEHD-CMK

Primary Target: caspase-9
View This Product on Sigma-Aldrich
218728
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
403848-57-7C₂₄H₃₅ClN₆O₉

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
218728-1MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 1 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA potent, irreversible inhibitor of caspase-9. Reported to reduce myocardial infarct size during reperfusion (~70 nM).
      Catalogue Number218728
      Brand Family Calbiochem®
      SynonymsAc-LEHD-CMK
      References
      ReferencesMocanu, M.M., et al. 2000. Br. J. Pharmacol. 130, 197.
      Product Information
      CAS number403848-57-7
      ATP CompetitiveN
      FormWhite solid
      FormulationSupplied as a trifluoroacetate salt.
      Hill FormulaC₂₄H₃₅ClN₆O₉
      Chemical formulaC₂₄H₃₅ClN₆O₉
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetcaspase-9
      Primary Target IC<sub>50</sub>70 nM against caspase-9
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Peptide SequenceAc-Leu-Glu-His-Asp-CMK
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Moisture Protect from moisture
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      218728-1MGCN 07790788048594

      Documentation

      Caspase-9 Inhibitor III - CAS 403848-57-7 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Caspase-9 Inhibitor III - CAS 403848-57-7 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      218728

      参考資料

      参考資料の概要
      Mocanu, M.M., et al. 2000. Br. J. Pharmacol. 130, 197.

      カタログ

      タイトル
      Caspases and other Apoptosis Related Tools Brochure
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision31-March-2011 RFH
      SynonymsAc-LEHD-CMK
      DescriptionA potent and irreversible inhibitor of caspase-9 (ICE-LAP6, Mch6). Reported to reduce myocardial infarct size during reperfusion (~70 nM).
      FormWhite solid
      FormulationSupplied as a trifluoroacetate salt.
      CAS number403848-57-7
      Chemical formulaC₂₄H₃₅ClN₆O₉
      Peptide SequenceAc-Leu-Glu-His-Asp-CMK
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (5 mg/ml) or (1 mg/ml) H₂O
      Storage Protect from moisture
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesMocanu, M.M., et al. 2000. Br. J. Pharmacol. 130, 197.